Exact Mass: 427.160725
Exact Mass Matches: 427.160725
Found 61 metabolites which its exact mass value is equals to given mass value 427.160725,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Moricizine
C22H25N3O4S (427.15656900000005)
Moricizine is only found in individuals that have used or taken this drug. It is an antiarrhythmia agent used primarily for ventricular rhythm disturbances. [PubChem]Moricizine works by inhibiting the rapid inward sodium current across myocardial cell membranes. D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
(1-(2-(Methylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-2-methoxy-1H-indole-3-carboxylate
C19H26FN3O5S (427.1577118000001)
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists
(7R)-8t-acetoxy-6,7-dimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-(7rN)-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinolin]-6t-ol|Raddeanidin|Raddeanidine
2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (2R,3R)-2,3-dihydroxybutanedioate
C16H29NO12 (427.16896740000004)
Flavoxate hydrochloride
C24H26ClNO4 (427.1550266000001)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D000089162 - Genitourinary Agents > D064804 - Urological Agents Flavoxate hydrochloride is a potent and competitive phosphodiesterase (PDE) inhibitor. Flavoxate hydrochloride is an antispasmodic agent and muscarinic mAChR antagonist. Flavoxate hydrochloride shows moderate calcium antagonistic activity and local anesthetic effect. Flavoxate hydrochloride can be used for the research of overactive bladder (OAB) and lower urinary tract infections[1].
3-[3-tert-butyl-5-(5-chlorobenzotriazol-2-yl)-4-hydroxyphenyl]propyl 2-methylprop-2-enoate
C23H26ClN3O3 (427.1662596000001)
3-Indoxyl Phosphate, Di-p-Toluidinium Salt
C22H26N3O4P (427.1660846000001)
4-Dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinecarboxylic acid 2-(2-hydroxyethoxy)ethyl ester
C22H25N3O4S (427.15656900000005)
(3r)-3-Cyclopentyl-6-Methyl-7-[(4-Methylpiperazin-1-Yl)sulfonyl]-3,4-Dihydro-2h-1,2-Benzothiazine 1,1-Dioxide
C19H29N3O4S2 (427.15993940000004)
N-(2-carbamoylphenyl)-2-(2,5-dimethoxyphenyl)quinoline-4-carboxamide
C25H21N3O4 (427.15319860000005)
Magnocurarine trifluoroacetate, rac-
C21H24F3NO5 (427.16064900000003)
A natural product found in Gnetum montanum.
1,4-Dimethyl-6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]quinoxaline-2,3-dione
C22H25N3O4S (427.15656900000005)
N-(2-furanylmethyl)-N-[(7-methyl-4-tetrazolo[1,5-a]quinolinyl)methyl]-2-phenoxyacetamide
C24H21N5O3 (427.16443160000006)
N,N-dimethyl-4-[[4-(5-methyl-1-benzotriazolyl)-1-piperidinyl]sulfonyl]benzamide
C21H25N5O3S (427.16780200000005)
3-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
C19H26FN3O5S (427.1577118000001)
3-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
C19H26FN3O5S (427.1577118000001)
3-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
C19H26FN3O5S (427.1577118000001)
3-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
C19H26FN3O5S (427.1577118000001)
3-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
C19H26FN3O5S (427.1577118000001)
(2R,3R,4S)-2-cyano-N-(2-fluorophenyl)-4-(hydroxymethyl)-3-[4-[(E)-2-phenylethenyl]phenyl]azetidine-1-carboxamide
3-[(3aS,4R,9bS)-1-[(2-fluorophenyl)-oxomethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
3-[(3aS,4S,9bS)-1-[(2-fluorophenyl)-oxomethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
[(1S)-7-methoxy-1-(3-methylphenyl)sulfonyl-1-spiro[1,2,3,9-tetrahydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
C22H25N3O4S (427.15656900000005)
3-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
C19H26FN3O5S (427.1577118000001)
3-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
C19H26FN3O5S (427.1577118000001)
3-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3,6-dihydro-2H-pyran-3-yl]benzenesulfonamide
C19H26FN3O5S (427.1577118000001)
3-[(3aR,4S,9bR)-1-[(2-fluorophenyl)-oxomethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
3-[(3aR,4R,9bR)-1-[(2-fluorophenyl)-oxomethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
2-Amino-3-[(3-butanoyloxy-2-hexanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[2,3-di(pentanoyloxy)propoxy-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(2-heptanoyloxy-3-propanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
3-[(3-Acetyloxy-2-octanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid
MORICIZINE
C22H25N3O4S (427.15656900000005)
D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
3-hydroxy-3-[(1r)-1-{6-hydroxy-5-[(methylsulfanyl)methyl]-3-(2-oxocyclopent-3-en-1-ylidene)-4,5-dihydro-2h-pyrazin-2-yl}ethyl]-1-methylindol-2-one
C22H25N3O4S (427.15656900000005)
(2s)-2-{[(2s,3r)-2-{[(2,3-dihydroxyphenyl)(hydroxy)methylidene]amino}-1,3-dihydroxybutylidene]amino}-5-(n-hydroxyacetamido)pentanoic acid
C18H25N3O9 (427.15907200000004)